Compounds > 9-deoxy-9-10-didehydro-12-13-didehydro-13-14-dihydroprostaglandin-d2

9-deoxy-9-10-didehydro-12-13-didehydro-13-14-dihydroprostaglandin-d2 and Leukemia--Myeloid

9-deoxy-9-10-didehydro-12-13-didehydro-13-14-dihydroprostaglandin-d2 has been researched along with Leukemia--Myeloid* in 1 studies

Other Studies

1 other study(ies) available for 9-deoxy-9-10-didehydro-12-13-didehydro-13-14-dihydroprostaglandin-d2 and Leukemia--Myeloid

Article	Year
Induction of c-fos protooncogene transcription and apoptosis by delta 12-prostaglandin J2 in human Pl-21 myeloid leukemia and RC-K8 pre-B lymphoma cells. Prostaglandins, 1996, Volume: 52, Issue:3 delta 12-prostaglandin J2 (PGJ2) is a dehydration product of PGD2 and thought to be the most potent antitumor agent among prostaglandin compounds. We examine the cytotoxic effects of PGJ2 on the cell growth of leukemia/lymphoma cells. PGJ2 inhibited the growth of both human PL-21 myeloid leukemia and RC-K8 pre-B lymphoma cells in culture in a dose-dependent manner with fragmentation of nucleus and formation of apoptotic body. Agarose gel electrophoresis revealed DNA ladder formation in the cells treated with PGJ2. Furthermore, PGJ2 induced a rapid and transient expression of apoptosis-related protooncogene, c-fos, in both cells. The gene transcriptional rate was remarkably increased approximately 3.3-fold in PGJ2 treated cells, but the stability of c-fos mRNA was not significantly changed. Inhibition of de novo protein synthesis with cycloheximide increased c-fos mRNA stability but not abrogated PGJ2-induced c-fos transcription. These data suggest that PGJ2 can induce apoptosis of human leukemia/lymphoma cells and the rapid activation of c-fos protooncogene transcription in which de novo protein synthesis is not required. Topics: Antineoplastic Agents; Apoptosis; Cell Division; DNA Fragmentation; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid; Lymphoma, B-Cell; Prostaglandin D2; Protein Biosynthesis; Proteins; Proto-Oncogene Proteins c-fos; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured	1996

Article

Year

Induction of c-fos protooncogene transcription and apoptosis by delta 12-prostaglandin J2 in human Pl-21 myeloid leukemia and RC-K8 pre-B lymphoma cells.

Prostaglandins, 1996, Volume: 52, Issue:3

delta 12-prostaglandin J2 (PGJ2) is a dehydration product of PGD2 and thought to be the most potent antitumor agent among prostaglandin compounds. We examine the cytotoxic effects of PGJ2 on the cell growth of leukemia/lymphoma cells. PGJ2 inhibited the growth of both human PL-21 myeloid leukemia and RC-K8 pre-B lymphoma cells in culture in a dose-dependent manner with fragmentation of nucleus and formation of apoptotic body. Agarose gel electrophoresis revealed DNA ladder formation in the cells treated with PGJ2. Furthermore, PGJ2 induced a rapid and transient expression of apoptosis-related protooncogene, c-fos, in both cells. The gene transcriptional rate was remarkably increased approximately 3.3-fold in PGJ2 treated cells, but the stability of c-fos mRNA was not significantly changed. Inhibition of de novo protein synthesis with cycloheximide increased c-fos mRNA stability but not abrogated PGJ2-induced c-fos transcription. These data suggest that PGJ2 can induce apoptosis of human leukemia/lymphoma cells and the rapid activation of c-fos protooncogene transcription in which de novo protein synthesis is not required.

Topics: Antineoplastic Agents; Apoptosis; Cell Division; DNA Fragmentation; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid; Lymphoma, B-Cell; Prostaglandin D2; Protein Biosynthesis; Proteins; Proto-Oncogene Proteins c-fos; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured

1996